Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback